Introduction {#Sec1}
============

Impaired *N*-methyl-[d]{.smallcaps}-aspartic acid (NMDA) receptor signaling and reduced levels of cyclic guanosine monophosphate (cGMP) have been demonstrated in animal models of schizophrenia \[[@CR1], [@CR2]\], and increasing evidence suggests that glutamatergic dysfunction may play a key role in mediating risk for conversion to psychosis \[[@CR3]--[@CR5]\]. Phosphodiesterase 9A (PDE9A), which has the highest affinity of all PDEs, hydrolyzes cGMP to regulate its intracellular concentration within glutamatergic neurons \[[@CR6]\]. Consequently, PDE9A inhibition may augment synaptic plasticity and memory function through increased cGMP availability and, thus, improved NMDA receptor signaling \[[@CR6], [@CR7]\]. PDE9A is highly expressed in the neocortex and hippocampus; therefore, it is likely to be a significant determinant of intracellular basal cGMP levels in these brain regions \[[@CR6], [@CR8]\].

BI 409306 is a potent and selective PDE9A inhibitor. Application of BI 409306 to rat hippocampal slices resulted in significant enhancement of long-term potentiation (LTP) \[[@CR9]\]. Furthermore, BI 409306 induced a dose-dependent increase in cGMP in rat cerebrospinal fluid (CSF) and prefrontal cortex and improved memory performance \[[@CR10]\]. In healthy male volunteers, BI 409306 was rapidly absorbed and eliminated and showed a good safety and tolerability profile \[[@CR11]--[@CR13]\]. In these studies, the most frequent adverse events (AEs) were visual symptoms such as photopsia (flashing light), photophobia (increased sensitivity to light), chromatopsia (change in color perception), and blurred vision. These AEs occurred shortly after administration and were resolved within 1--2 h. In a proof-of-mechanism study conducted in healthy male volunteers, BI 409306 administered orally as a single dose crossed the blood--brain barrier and triggered a dose- and concentration-dependent increase in cGMP in the CSF \[[@CR14]\].

The objective of this study was to investigate the safety and tolerability of BI 409306, a novel PDE9 inhibitor, in patients with mild-to-moderate schizophrenia. The associated pharmacokinetics (PK) and cognitive outcomes were also explored. BI 409306 was administered orally at a dosage of 25, 50, or 100 mg for 14 days.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a randomized, double-blind, placebo-controlled, parallel-group, phase I study in patients with mild-to-moderate schizophrenia. The study was conducted from 8 July 2013 to 5 December 2013 at the Community Clinical Research, Inc., Austin, TX. The duration of the study from screening through completion of the end-of-treatment visit was up to 8 weeks. The end-of-treatment visit was planned 7--14 days after the administration of the last dose of the study drug (Fig. [1](#Fig1){ref-type="fig"}). Patients were randomized (1:1:1:1) on day 1 to receive BI 409306 at 25, 50, or 100 mg or placebo, administered orally once daily (qd) for 14 days. Sequentially numbered blinded medication kits were assigned to the patients at the study site. All the patients provided written informed consent. All procedures followed in the study (ClinicalTrials.gov: NCT01892384) were in accordance with the protocol, ethical standards laid down in the Helsinki Declaration of 1964 (as revised in 2013), the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice, and relevant Boehringer Ingelheim standard operating procedures.Fig. 1Study design

Patients {#Sec4}
--------

Patients included in the study were 18--55 years of age, with an established diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria, with the following clinical features: clinically stable and in the residual (non-acute) phase of illness or maintained on current antipsychotic medications and dose for ≥ 8 weeks; and having no more than a "moderate" severity rating on hallucinations and delusions, positive formal thought disorder and negative symptoms, and minimal extrapyramidal and depressive symptoms. All patients were genotyped for cytochrome P450 2C19 (CYP2C19).

Patients were excluded if they were treated with \> 1 antipsychotic agent, not stabilized on antipsychotic treatment, or had electroconvulsive therapy within the last 30 days, or if the severity of their cognitive impairment would affect the study outcome in the clinical judgment of the investigator. In addition, patients with any of the following were excluded from the study: suicidal behavior within the past 2 years or type 4 or 5 suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) within the past 3 months; findings from medical examination or laboratory values deviating from normal limits and of clinical relevance; planned elective surgery; a history or diagnosis of symptomatic and unstable/uncontrolled gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hematological, or hormonal disorders; a history or new diagnosis of human immunodeficiency virus infection or malignancy; or a history of neurologic or psychiatric condition that might interfere with the interpretation of data. Pregnant or breastfeeding women were also excluded.

Study Assessments {#Sec5}
-----------------

### Safety Endpoints {#Sec6}

The primary endpoints for safety and tolerability were evaluated based on AEs, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory tests, physical examination, Clinical Global Impression--Improvement (CGI-I) scale, disease severity on the Positive and Negative Syndrome Scale (PANSS), suicidality assessment by the C-SSRS, and visual acuity and color vision assessed by Snellen chart and Ishihara plates, respectively.

### Pharmacokinetic Endpoints {#Sec7}

The following PK parameters were assessed as secondary endpoints: area under the plasma concentration--time curve of BI 409306 from zero extrapolated to infinity after a single dose (AUC~0−∞~); area under the plasma concentration--time curve of BI 409306 in plasma at steady state over a uniform dosing interval tau (AUC~tau,ss~); maximum measured concentration of BI 409306 in plasma following a single dose (*C* ~max~) and at steady state (*C* ~max,ss~); time from dosing to maximum measured concentration of BI 409306 in plasma following a single dose (*t* ~max~) and at steady state (*t* ~max,ss~); and terminal elimination half-life of BI 409306 (*t* ~1/2~).

### Cognitive Outcomes {#Sec8}

Additional secondary endpoints included measurement of the total score on the Hopkins Verbal Learning Test--Revised (HVLT-R) and total score on the Brief Visuospatial Memory Test--Revised (BVMT-R).

Statistical Analyses {#Sec9}
--------------------

Dose proportionality was explored after a single dose (day 1, *C* ~max~ and AUC~0−∞~) and after multiple dosing (day 14, *C* ~max,ss~ and AUC~tau,ss~) using a linear regression model with log-transformed dose as an independent variable applied to log-transformed data. Two-sided 95% confidence intervals (CIs) for the slope were computed from this model. For PK endpoints AUC~0−∞~ and AUC~tau,ss~, a linear model with patient and order as fixed effects was applied to log-transformed data to assess linearity for each dose separately. Attainment of steady state was assessed using a linear model with patient as a fixed effect, time as a repeated effect, and log-transformed pre-dose concentration from days 1 to 14 as the dependent variable for each dose separately.

Changes in HVLT-R and BVMT-R total scores were compared between doses of BI 409306 and placebo using an analysis of covariance model with treatment as a fixed effect and baseline as a covariate. Safety analyses were performed for all patients who received ≥ 1 dose of the study drug; the results are summarized descriptively.

Results {#Sec10}
=======

Patient Characteristics {#Sec11}
-----------------------

Of the 50 patients enrolled, 40 were randomized to receive either BI 409306 or placebo; 38 patients completed the study and two withdrew consent (Fig. [2](#Fig2){ref-type="fig"}). There were four important protocol deviations: one patient in the 25-mg group received a prohibited medication (lorazepam) on day 7; one patient in the 50-mg group tested positive for cocaine on day −1, but had initiated treatment before the drug screen results were available; another patient had a prior suicide attempt; and one patient in the placebo group declined to provide informed consent for the optional pharmacogenetic sample collection for DNA banking. However, none of these patients were excluded from the study analysis. Patients were predominantly male (87.5%) and African American (52.5%) or white (47.5%), with a mean (standard deviation \[SD\]) age of 40.2 (9.0) years. Demographics and baseline characteristics were well balanced across all treatment groups, with the exception of cognition (HVLT-R and BVMT-R; Table [1](#Tab1){ref-type="table"}). As BI 409306 oxidative metabolism is dependent on CYP2C19, CYP2C19 phenotype was predicted for each patient based on genotype. Of the 40 randomized patients, 16 (40.0%) were predicted to be ultra-rapid metabolizers (UM) for CYP2C19; 11 (27.5%), extensive metabolizers (EM); and 8 (20.0%), intermediate metabolizers (IM). No patients were predicted to be poor metabolizers (PM) for CYP2C19. For five patients, the predicted CYP2C19 phenotype could not be determined based on genotype.Fig. 2Patient disposition Table 1Patient demographics and baseline characteristicsBI 409306Placebo (*n* = 10)Total (*N* = 40)25 mg (*n* = 10)50 mg (*n* = 10)100 mg (*n* = 10)Mean age (SD), years37.9 (9.5)42.5 (9.0)42.5 (8.4)37.8 (9.5)40.2 (9.0)Gender,*n* (%) Male10 (100.0)7 (70.0)10 (100.0)8 (80.0)35 (87.5) Female--3 (30.0)--2 (20.0)5 (12.5)Race,*n* (%) African American5 (50.0)4 (40.0)7 (70.0)5 (50.0)21 (52.5) White5 (50.0)6 (60.0)3 (30.0)5 (50.0)19 (47.5)BMI, kg/m^2^26.0 (5.6)31.5 (4.3)29.1 (6.1)28.7 (5.2)28.8 (5.5)HVLT-R score17.9 (5.5)18.4 (3.7)16.9 (6.4)19.5 (5.2)18.2 (5.2)BVMT-R score9.2 (10.3)17.5 (3.8)12.9 (7.9)16.2 (10.3)14.0 (8.8)Smoking status,*n* (%) Never smoked--1 (10.0)1 (10.0)3 (30.0)5 (12.5) Ex-smoker--1 (10.0)3 (30.0)--4 (10.0) Current smoker10 (100.0)8 (80.0)6 (60.0)7 (70.0)31 (77.5)Alcohol status,*n* (%) Non-drinker10 (100)9 (90.0)9 (90.0)10 (100.0)38 (95.0) Drinks--no interference--1 (10.0)1 (10.0)--2 (5.0)Treated set includes all patients who received at least 1 dose of study medicationData are presented as mean (SD), unless indicated otherwise*BMI* body mass index, *BVMT-R* Brief Visuospatial Memory Test--Revised, *HVLT-R* Hopkins Verbal Learning Test--Revised, *SD* standard deviation

Safety {#Sec12}
------

Table [2](#Tab2){ref-type="table"} summarizes the AEs. BI 409306 was well tolerated; treatment-emergent AEs were reported in 23 (57.5%) patients. All AEs were mild in intensity, and no apparent dose-related trends were observed for any AE. Eleven (27.5%) patients reported a total of 13 eye-related AEs, including blurred vision (*n* = 8), photopsia (flashing lights; *n* = 2), visual impairment (*n* = 2), and visual field defect (*n* = 1). The number of patients reporting eye-related AEs was similar across all BI 409306 dose groups and the placebo group. All eye-related AEs were non-serious and mild in intensity, and resolved spontaneously without medical treatment. All but three events (blurred vision in one patient each in the 25-mg and 50-mg groups, and visual field defect in one patient in the 100-mg group) were assessed as related to treatment. There were no deaths, serious AEs or discontinuation due to AEs. The incidence of treatment-emergent AEs was similar between BI 409306 and placebo. No clinically relevant or dose-related changes were observed in laboratory parameters, vital signs, or ECGs in patients receiving BI 409306 or placebo.Table 2Summary of adverse eventsSystem organ class/preferred termBI 409306Placebo (*n* = 10)\
*n* (%)Total (*N* = 40)\
*n* (%)25 mg (*n* = 10)\
*n* (%)50 mg (*n* = 10)\
*n* (%)100 mg (*n* = 10)\
*n* (%)Total with adverse events4 (40.0)9 (90.0)6 (60.0)4 (40.0)23 (57.5)Infections and infestations--1 (10.0)1 (10.0)--2 (5.0) Furuncle--1 (10.0)----1 (2.5) Tooth infection----1 (10.0)--1 (2.5)Psychiatric disorders1 (10.0)--2 (20.0)1 (10.0)4 (10.0) Agitation----1 (10.0)1 (10.0)2 (5.0) Anxiety1 (10.0)--1 (10.0)--2 (5.0)Nervous system disorders1 (10.0)1 (10.0)2 (20.0)--4 (10.0) Dizziness1 (10.0)------1 (2.5) Headache--1 (10.0)1 (10.0)--2 (5.0) Tremor----1 (10.0)--1 (2.5) Visual field defect----1 (10.0)--1 (2.5)Eye disorders2 (20.0)4 (40.0)2 (20.0)2 (20.0)10 (25.0) Vision blurred2 (20.0)3 (30.0)1 (10.0)2 (20.0)8 (20.0) Photopsia--1 (10.0)1 (10.0)--2 (5.0) Visual impairment1 (10.0)1 (10.0)----2 (5.0)Gastrointestinal disorders2 (20.0)--1 (10.0)--3 (7.5) Gastroesophageal reflux disease1 (10.0)------1 (2.5) Nausea1 (10.0)------1 (2.5) Toothache----1 (10.0)--1 (2.5) Vomiting1 (10.0)------1 (2.5)Musculoskeletal and connective tissue disorders--3 (30.0)----3 (7.5) Musculoskeletal pain--2 (20.0)----2 (5.0) Back pain--1 (10.0)----1 (2.5)General disorders and administration site conditions----1 (10.0)1 (10.0)2 (5.0) Pain----1 (10.0)--1 (2.5) Pre-existing condition improved------1 (10.0)1 (2.5)Injury, poisoning, and procedural complications--1 (10.0)1 (10.0)--2 (5.0) Excoriation--1 (10.0)1 (10.0)--2 (5.0)Percentages are calculated using total number of patients per treatment as the denominator

CGI-I indicated no change or minimal improvement in the patients' overall disease status. The mean change from baseline in total PANSS scores for the 25-, 50-, and 100-mg BI 409306 and placebo groups were −0.1, −0.2, −1.4, and −0.9, respectively, at day 7, and 2.3, 0.0, −3.6, and 0.0, respectively, at day 13, suggesting no deterioration in disease symptoms or clinical status. Mild suicidal ideation after treatment initiation (C-SSRS score = 1) was reported in one patient each in the 50-mg BI 409306 and placebo groups. Changes in visual acuity were reported intermittently for a few patients across all treatment groups. Color discrimination was reported as normal at maximum time points in all the patients. Visual examination of box-plots of *C* ~max,ss~ of BI 409306 or its major metabolites did not suggest any association between higher exposure and worsening of visual acuity or color vision. Administration of BI 409306 had a negligible effect on the mean pupil diameter relative to placebo.

Pharmacokinetics {#Sec13}
----------------

PK profiles of BI 409306 following single- and multiple-dose administration were characterized by a rapid increase in plasma concentration and rapid elimination. Table [3](#Tab3){ref-type="table"} shows the PK endpoints after single- and multiple-dose administration of BI 409306. After single-dose administration, BI 409306 was rapidly absorbed, reaching *C* ~max~ within 30--45 min (Fig. [3](#Fig3){ref-type="fig"}). Following absorption, BI 409306 was rapidly eliminated, with geometric mean (gMean) *t* ~1/2~ ranging from 1.10 to 1.85 h. After multiple-dose administration, BI 409306 was rapidly absorbed, with *C* ~max,ss~ attained within the first hour after dosing. Total exposure at steady state was similar to that following a single dose, with an accumulation ratio close to 1 (ranges: AUC 0.758--1.13; *C* ~max~ 0.768--1.40), indicating minor to no accumulation with multiple dosing.Table 3Pharmacokinetic endpoints after single- and multiple-dose administration of BI 409306BI 40930625 mg (*n* = 10)50 mg (*n* = 10)100 mg (*n* = 10)AUC~0−∞~, nmol∙h/L217 (107)770 (98.4)2020 (108)AUC~tau,ss~, nmol∙h/L147 (112)969 (104)2280 (86.8)*C* ~max~, nmol/L138 (91.9)431 (73.3)998 (106)*C* ~max,ss~, nmol/L99.2 (86.8)631 (90.9)1290 (74.4)*t* ~max~, h^a^0.63 (0.33--1.50)0.63 (0.33--2.0)0.75 (0.33--2.0)*t* ~max,ss~, h^a^0.75 (0.33--1.0)0.33 (0.33--1.5)0.63 (0.33--1.5)*t* ~1/2~, h1.10 (43.1)1.57 (27.0)1.85 (31.0)RA, *C* ~max~0.768 (42.5)1.40 (23.9)1.29 (61.4)RA, AUC0.758 (26.9)1.13 (17.8)1.13 (42.5)Pharmacokinetic (PK) set included all patients in the treated set who had no important protocol violation(s) relevant to the evaluation of PK parameters and who provided at least 1 evaluable observation for a PK endpointData are presented as geometric mean (% gCV) unless otherwise noted^a^Median (min--max)AUC~0−∞~, area under the plasma concentration--time curve of the analyte from zero extrapolated to infinity after single dose; AUC~tau,ss~, area under the plasma concentration--time curve of the analyte in plasma at steady state over a uniform dosing interval tau; *C* ~max,ss~, maximum measured concentration in plasma following a single dose (and at steady state); gCV, geometric coefficient of variation; RA, AUC, accumulation ratio of the analyte in plasma at steady state corresponding to the ratio of AUC~tau,ss~ to AUC~0−∞~; RA, *C* ~max~, accumulation ratio of the analyte in plasma at steady state corresponding to the ratio of *C* ~max,ss~ to *C* ~max~; *t* ~max,ss~, time from dosing to maximum measured concentration in plasma following a single dose (and at steady state); *t* ~1/2~, terminal elimination half-life Fig. 3Geometric mean plasma concentration--time profiles after single and multiple doses of BI 409306 (25, 50, and 100 mg)

Dose-normalized gMean *C* ~max~, *C* ~max,ss~, AUC~0−∞~ and AUC~tau,ss~ values were similar for the 50- and 100-mg dose groups following single- and multiple-dose administration, suggesting dose proportionality. However, dose-normalized parameters for the 25-mg dose group were lower than expected, with approximately threefold lower *C* ~max,ss,norm~ and AUC~tau,ss,\ norm~ compared with the higher dose groups. Linearity with respect to multiple dose administration could not be established due to high inter-individual variability in the linearity index within each dose group.

Inter-individual variability in BI 409306 PK parameters was moderate to high. The geometric coefficient of variation (gCV) after a single dose ranged from 98.4% to 108% for AUC~0−∞~ and from 73.3% to 106% for *C* ~max~; gCV at steady state ranged from 86.8% to 112% for AUC~tau,ss~ and from 74.4% to 90.9% for *C* ~max,ss~. Exposure was highest in patients with the CYP2C19 IM predicted phenotype, followed by EM and UM patients. However, inter-individual variability was lower in the IM patients than in the EM and UM patients, with gCV% of 48.4%, 152%, and 154%, respectively.

Cognitive Outcomes {#Sec14}
------------------

No significant treatment differences were observed with 25-, 50-, or 100-mg BI 409306 in HVLT-R total scores (*p* = 0.0867, *p* = 0.2011, and *p* = 0.4103, respectively) or BVMT-R total scores (*p* = 0.5791, *p* = 0.605, and *p* = 0.7171, respectively) compared with placebo.

Discussion {#Sec15}
==========

In this study, BI 409306 at a dosage of 25, 50, or 100 mg per day for 14 days was well tolerated in patients with mild-to-moderate schizophrenia. The PK of BI 409306 following single- and multiple-dose administration was characterized by very rapid absorption followed by rapid monophasic to biphasic elimination. No evidence of deterioration in schizophrenia symptoms, suicidality, or overall clinical status was observed in this study.

The safety results for BI 409306 in this study are comparable to those from studies conducted in healthy male volunteers. In previous studies, AEs were mild to moderate in intensity and of short duration \[[@CR11], [@CR14]\]. The most frequently reported AEs were visual AEs. Consistent with the present study, there was no apparent dose-dependent increase in AEs \[[@CR14]\]. In young and elderly healthy subjects administered 25, 50, or 100 mg BI 409306 or placebo, a majority of the AEs were mild in intensity, with a dose-dependent increase in subjects reporting eye disorders such as photophobia (increased sensitivity to light), chromatopsia (change in color perception), visual impairment, blurred vision, abnormal sensation in the eye, asthenopia, and eye pain \[[@CR12]\]. Similarly, in healthy male Chinese and Japanese subjects, most AEs were mild; the most frequently reported AEs in subjects receiving BI 409306 were eye disorders (29.8%), which were resolved within 1--2 h \[[@CR13]\]. Visual side effects have been proposed to be associated with PDE9A, which regulates the level of cGMP by hydrolyzing it and modulates inhibitory processes in the cone pathway of the retina \[[@CR15]\]. Given the results in healthy subjects, eye-related AEs were of interest in this study, and indeed, these were the most frequently reported AEs. Unlike previous studies, however, eye-related AEs in this study were reported with similar frequency in all treatment groups. Overall, changes in visual acuity were reported intermittently and with similar severity and frequency by patients across treatment groups, and were typically mild and transient. While some changes in visual acuity in BI 409306-treated patients occurred around the anticipated time of peak plasma concentrations of BI 409306, a consistent relationship between changes in visual acuity and BI 409306 *C* ~max~ was not observed. Interestingly, the frequency of total AEs in this study is comparable to that of a study in which the selective PDE9A inhibitor PF-04447943 was used in patients with mild-to-moderate probable Alzheimer's disease \[[@CR16]\].

The PK of BI 409306 in this study is in line with that observed in previous studies in healthy subjects, which is characterized by very rapid absorption and elimination, with minor accumulation. In the current study, exposure was dose-proportional from 50 to 100 mg and was comparable to that observed in a previous study \[[@CR12]\]. However, exposure in the 25-mg dose group was lower than expected, resulting in a lack of dose proportionality over the 25- to 100-mg dose range. Linearity with respect to multiple-dose administration could not be established due to the high inter-subject variability in the linearity index within each dose group. This variability could be partly due to differences in CYP2C19 predicted phenotype, as exposure in IM was highest, followed by exposure in EM and UM.

A previous study reported that BI 409306 crossed the blood--brain barrier, with the maximum concentration in CSF reaching 28.31% of the maximum plasma concentration \[[@CR14]\]. BI 409306 had no effect on the chosen cognitive tests over the 14-day treatment period in patients with schizophrenia; however, that study was not of sufficient power or duration to adequately assess the overall effect on cognition \[[@CR17]\]. In a phase II placebo-controlled study, PF-04447943 reached maximal concentrations of approximately five times the IC50 \[[@CR16]\]. Moreover, the estimated median exposure remained above the IC50 for the entire dosing duration. Treatment with PF-04447943 over a 12-week period was not more effective than placebo in terms of cognition, behavior, or clinician-rated global change.

A limitation of this study is that the population was drawn from a single center. Furthermore, the patients who participated in this study may not represent the larger population with chronic schizophrenia, many of whom are on multiple medications or on medications that were excluded. Nevertheless, the study results provide guidance for design of future trials with BI 409306.

Conclusion {#Sec16}
==========

Overall, BI 409306 showed satisfactory safety and tolerability at 25-, 50-, or 100-mg qd doses for 14 days in patients with mild-to-moderate schizophrenia. The PK profile of BI 409306 was characterized by rapid absorption, rapid monophasic to biphasic elimination, and minor accumulation with multiple dosing. There were no apparent effects on cognitive function over 14 days of treatment with BI 409306.
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